Understanding Glutaric Acidemia Type II
Also known as multiple acyl-CoA dehydrogenase deficiency, this inherited disorder disrupts the body's ability to break down fats and certain amino acids, ranging from a severe neonatal form to a milder, later-onset presentation.
- Newborn Screening Detectable
- Fasting Avoidance Critical
- Riboflavin-Responsive in Some Cases
- Specialist Metabolic Care
- Estimated Incidence
- Rare; precise figures vary by population
- Severe Form Onset
- Birth (often with congenital anomalies)
- Inheritance Pattern
- Autosomal recessive
- Care Focus
- Fasting Avoidance, Riboflavin Trial, Emergency Protocols
Condition Overview
Glutaric acidemia type II, also called multiple acyl-CoA dehydrogenase deficiency (MADD), is an inherited disorder that impairs the body's ability to break down fatty acids and certain amino acids for energy. It is caused by defects in the electron transfer flavoprotein system (ETFA, ETFB, or ETFDH genes), which normally supports multiple metabolic pathways.
The condition exists on a spectrum. The most severe neonatal-onset form can present at birth with congenital anomalies, profound metabolic crisis, and is often life-threatening in the newborn period. A neonatal-onset form without congenital anomalies and a milder, later-onset form with episodic symptoms triggered by fasting or illness are also recognized.
Because the body cannot efficiently use fat for energy during times of increased need, such as fasting or illness, avoiding prolonged fasting and having a clear emergency management plan are central to protecting health, particularly in the more severe forms.
Clinical Subtypes
GA2/MADD is classified by age of onset, severity, and presence of associated congenital anomalies.
Symptoms and Signs
Symptoms vary widely depending on subtype, ranging from severe presentation at birth to episodic symptoms later in life.
Causes and Risk Factors
GA2/MADD is caused by inherited mutations affecting the electron transfer flavoprotein system required for multiple fatty acid and amino acid oxidation pathways.
Diagnosis and Investigations
Diagnosis often begins with newborn screening but requires confirmatory biochemical, imaging, and genetic evaluation.
Disease Severity Classification
GA2/MADD is not staged like a malignancy, but clinical severity is generally categorized by the recognized clinical subtypes.
Standard Treatment Options
Treatment focuses on avoiding metabolic stress, supporting energy needs through dietary strategies, and managing acute decompensation promptly.
Advanced and Emerging Treatment Options
Beyond standard dietary and emergency management, several specialized and emerging approaches are relevant to GA2/MADD, particularly the late-onset form.
Vitamin-Responsive Therapy
High-dose riboflavin
Certain ETFDH genotypes associated with the late-onset form can show substantial clinical improvement with riboflavin supplementation.
Precision Medicine
Genotype-informed prognosis counseling
Identifying the specific gene and mutation type helps predict severity and likelihood of treatment responsiveness.
Specialized Nutrition
Medium-chain triglyceride-based dietary plans
Metabolic dietitian-guided diets help provide an alternative energy source that bypasses the affected pathway.
Gene Therapy
Investigational gene-based approaches
Early-stage research is exploring gene therapy strategies for severe fatty acid oxidation and electron transfer flavoprotein disorders.
Biomarkers and Monitoring Parameters
Biochemical markers guide diagnosis, monitoring, and assessment of metabolic control in GA2/MADD.
When a Second Opinion May Be Important
Several scenarios in GA2/MADD management benefit from specialist metabolic genetics review.
Clinical Trials and Research
Prognosis and Key Outcome Factors
Prognosis in GA2/MADD varies widely by subtype: the severe neonatal-onset forms, particularly with congenital anomalies, carry a guarded outlook, while the late-onset form often has a more favorable course with proactive management and, in some cases, riboflavin responsiveness.
Supportive Care and Living With Glutaric Acidemia Type II
Living with GA2/MADD involves careful attention to fasting avoidance, dietary planning, and coordinated specialist care across the lifespan.
How CancerFax Helps You Explore Treatment Options
CancerFax can help you organize newborn screening and metabolic test results, coordinate a second opinion with a metabolic genetics specialist, and connect you with centers experienced in managing the full spectrum of GA2/MADD.
Get a free case reviewFrequently Asked Questions
Glutaric acidemia type II, also known as multiple acyl-CoA dehydrogenase deficiency, is an inherited disorder that impairs the body's ability to break down fats and certain amino acids for energy.
Signs vary by subtype but can include poor feeding, lethargy, a distinctive body odor in severe neonatal cases, or episodic vomiting and weakness in milder, later-onset forms.
Diagnosis often begins with newborn screening showing a broad acylcarnitine elevation pattern and is confirmed through urine organic acid analysis and genetic testing of the ETFA, ETFB, or ETFDH genes.
There is no cure, but the late-onset form can sometimes respond well to riboflavin supplementation, and dietary management combined with fasting avoidance helps reduce crisis risk across subtypes.
GA2/MADD is inherited in an autosomal recessive pattern, meaning both parents typically carry a gene variant. Genetic counseling can clarify individual family risk.
Severity depends largely on which gene is affected and the specific mutation type, ranging from a severe neonatal presentation to a much milder, later-onset form.
Because the body cannot efficiently use fat for energy, prolonged fasting forces reliance on an impaired pathway, which can rapidly lead to dangerous low blood sugar and metabolic acidosis.
In some patients with the late-onset form and certain ETFDH genotypes, high-dose riboflavin can lead to meaningful clinical improvement, though responsiveness varies by individual genotype.
Researchers are studying gene-based approaches and refined dietary strategies, though current management relies on fasting avoidance, dietary modification, and riboflavin trials where appropriate.
Yes. CancerFax can help you organize your metabolic test reports, facilitate a second opinion with a metabolic genetics specialist, and coordinate access to centers experienced in managing GA2/MADD across its full severity spectrum.
Get Support Managing Glutaric Acidemia Type II
Connect with metabolic specialists experienced in fatty acid oxidation disorders and long-term care planning.